Age and Obesity Promote Methylation and Suppression of 5α-Reductase 2: Implications for Personalized Therapy of Benign Prostatic Hyperplasia
Authors:
- 1 October 2015
- journal article
- Published by Wolters Kluwer Health in Journal of Urology
- Vol. 194 (4) , 1031-1037
Abstract
In men with symptomatic benign prostatic hyperplasia 5α-reductase inhibitors are a main modality of treatment. More than 30% of men do not respond to the therapeutic effects of 5α-reductase inhibitors. We have found that a third of adult prostate samples do not express 5α-reductase type 2 secondary to epigenetic modifications. We evaluated whether 5α-reductase type 2 expression in benign prostatic hyperplasia specimens from symptomatic men was linked to methylation of the 5α-reductase type 2 gene promoter. We also identified associations with age, obesity, cardiac risk factors and prostate specific antigen. Prostate samples from men undergoing transurethral prostate resection were used. We determined 5α-reductase type 2 protein expression and gene promoter methylation status by common assays. Clinical variables included age, body mass index, hypertension, hyperlipidemia, diabetes, prostate specific antigen and prostate volume. Univariate and multivariate statistical analyses were performed followed by stepwise logistic regression modeling. Body mass index and age significantly correlated with methylation of the 5α-reductase type 2 gene promoter (p <0.05) whereas prostate volume, prostate specific antigen or benign prostatic hyperplasia medication did not correlate. Methylation highly correlated with 5α-reductase protein expression (p <0.0001). In a predictive model increasing age and body mass index significantly predicted methylation status and protein expression (p <0.01). Increasing age and body mass index correlate with increased 5α-reductase type 2 gene promoter methylation and decreased protein expression in men with symptomatic benign prostatic hyperplasia. These results highlight the interplay among age, obesity and gene regulation. Our findings suggest an individualized epigenetic signature for symptomatic benign prostatic hyperplasia, which may be important to choose appropriate personalized treatment options.Keywords
This publication has 30 references indexed in Scilit:
- The Expanding Role of Epigenetics in the Development, Diagnosis and Treatment of Prostate Cancer and Benign Prostatic HyperplasiaJournal of Urology, 2007
- Metabolic Factors Associated with Benign Prostatic HyperplasiaThe Journal of Clinical Endocrinology & Metabolism, 2006
- Obesity, Serum Prostate Specific Antigen and Prostate Size: Implications for Prostate Cancer DetectionJournal of Urology, 2006
- Central Obesity as a Risk Factor for Prostatic HyperplasiaObesity, 2006
- ECONOMIC COSTS OF BENIGN PROSTATIC HYPERPLASIA IN THE PRIVATE SECTORJournal of Urology, 2005
- Persistent c-FLIP(L) Expression Is Necessary and Sufficient to Maintain Resistance to Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand–Mediated Apoptosis in Prostate CancerCancer Research, 2004
- The Influence of Finasteride on the Development of Prostate CancerNew England Journal of Medicine, 2003
- The Effect of Finasteride on the Risk of Acute Urinary Retention and the Need for Surgical Treatment among Men with Benign Prostatic HyperplasiaNew England Journal of Medicine, 1998
- Etiology of Benign Prostatic HyperplasiaEuropean Urology, 1994
- The Development of Human Benign Prostatic Hyperplasia with AgeJournal of Urology, 1984